Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma

Effects of Ageing on the Immune System: Infants to Elderly

(2016) R. Valiathan et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E -TCL1 CLL mouse model

(2015) F. McClanahan et al.   BLOOD

Pathogenesis beyond the cancer clone(s) in multiple myeloma

(2015) G. Bianchi et al.   BLOOD

Immunotherapy for multiple myeloma: Current status and future directions

(2015) Ayed O. Ayed et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Novel therapeutic strategies for multiple myeloma

(2015) Naoya Mimura et al.   EXPERIMENTAL HEMATOLOGY

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

(2015) Camille Guillerey et al.   JOURNAL OF CLINICAL INVESTIGATION

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

(2015) Arianna Calcinotto et al.   OncoImmunology

Shaping the repertoire of tumor-infiltrating effector and regulatory T cells

(2014) Peter A. Savage et al.   IMMUNOLOGICAL REVIEWS

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

(2013) C Bryant et al.   Blood Cancer Journal

Lenalidomide in multiple myeloma: Current status and future potential

(2012) Hang Quach et al.   AMERICAN JOURNAL OF HEMATOLOGY

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?

(2012) Andy Hsu et al.   OncoImmunology

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

(2011) S. J. Harrison et al.   BLOOD

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

(2010) K. Noonan et al.   BLOOD

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

(2010) R. H. Prabhala et al.   BLOOD

Drug-mediated and cellular immunotherapy in multiple myeloma

(2010) David S Ritchie et al.   Immunotherapy

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

(2008) K. M. Dhodapkar et al.   BLOOD

Modeling Multiple Myeloma by AID-Dependent Conditional Activation of MYC

(2008) W. Michael Kuehl   CANCER CELL

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy

(2008) Simon J. Harrison et al.   LEUKEMIA & LYMPHOMA

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

(2008) Sven Koch et al.   Immunity & Ageing